2026-2027 | Live Session | Novel Psychoactive Substances | October 2026-Novel Psychoactive Substances Presentation

Novel Psychoactive Substances Presentation

Pdf Summary

The lecture surveys novel psychoactive substances (NPS), designer drugs, and emerging products sold online or in convenience stores. These substances are often mislabeled, adulterated, or chemically changing, so a product’s name or appearance cannot reliably identify its contents. Routine drug screens may miss them; confirmatory testing such as mass spectrometry may be needed.<br /><br />Major drug groups discussed include MDMA and its substitutes, synthetic cathinones, synthetic cannabinoids, NBOMe hallucinogens, synthetic benzodiazepines, kratom-derived products, tianeptine, kava, hemp-derived cannabinoids, and mushroom edibles. Intoxication can involve agitation, confusion, psychosis, seizures, abnormal heart rate or blood pressure, hyperthermia, and other serious complications. Synthetic cannabinoids may also cause prolonged psychosis, while kratom and tianeptine can lead to dependence and withdrawal. Products marketed as “pink cocaine,” “Molly,” or “gas station heroin” may contain entirely different drugs than advertised.<br /><br />The presenters emphasize supportive, symptom-based care: calm and sedate agitated patients—often with benzodiazepines—while cooling and hydrating when appropriate. Manage specific complications such as seizures, rhabdomyolysis, and hyponatremia; use fluid restriction when low sodium is present. Give naloxone when opioid-related respiratory depression is suspected, even if the exact substance is unclear. Withdrawal may require treatment with medications for opioid use disorder or other symptom-directed care.<br /><br />The lecture also distinguishes cutting agents, intentionally added adulterants, and accidental contaminants. Examples include levamisole in cocaine; brodifacoum in synthetic cannabinoids; xylazine and the increasingly detected sedative medetomidine in the opioid supply; and potentially toxic contaminants in hemp-derived products. Overall, clinicians should avoid relying on product labels or routine toxicology results, assess for mixed-drug exposure, and remain alert to evolving local drug supplies and associated risks.

Keywords

novel psychoactive substances

designer drugs

synthetic cathinones

synthetic cannabinoids

MDMA substitutes

mass spectrometry

adulterants and contaminants

naloxone

drug intoxication

harm reduction